| Title |
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
|
|---|---|
| Published in |
International Journal of Chronic Obstructive Pulmonary Disease, February 2014
|
| DOI | 10.2147/copd.s51592 |
| Pubmed ID | |
| Authors |
Walter Vincken, Joseph Aumann, Hungta Chen, Michelle Henley, Danny McBryan, Pankaj Goyal |
| Abstract |
Addition of a second bronchodilator from a different pharmacological class may benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) whose symptoms are insufficiently controlled by bronchodilator monotherapy. GLOW6 evaluated the efficacy and safety of once-daily coadministration of the long-acting β2-agonist indacaterol (IND) and the long-acting muscarinic antagonist glycopyrronium (GLY) versus IND alone in patients with moderate-to-severe COPD. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 126 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 2% |
| United States | 1 | <1% |
| Unknown | 123 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 19 | 15% |
| Other | 14 | 11% |
| Student > Bachelor | 14 | 11% |
| Researcher | 13 | 10% |
| Student > Ph. D. Student | 8 | 6% |
| Other | 23 | 18% |
| Unknown | 35 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 52 | 41% |
| Nursing and Health Professions | 9 | 7% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Agricultural and Biological Sciences | 5 | 4% |
| Other | 7 | 6% |
| Unknown | 43 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2019.
All research outputs
#4,659,519
of 25,373,627 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#548
of 2,577 outputs
Outputs of similar age
#52,032
of 322,718 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#10
of 29 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,577 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,718 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.